The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
AIMS: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus. METHODS: Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25 kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator. RESULTS: In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2 mg/week: -1.62 kg (95% CrI: -2.95 kg, -0.30 kg), exenatide 20 μg: -1.37 kg (95% CI: -222 kg, -0.52 kg), liraglutide 1.2 mg: -1.01 kg (95%CrI: -2.41 kg, 0.38 kg) and liraglutide 1.8 mg: -1.51 kg (95% CI: -2.67 kg, -0.37 kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss. CONCLUSIONS: This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 analogues also induce weight loss, which is associated with improved T2D prognosis.252,262,263”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [263]
In the citing paper
“GLP-1 analogues are also consistently more effective at inducing weight loss than most oral glucose-lowering drugs and insulin.262,263”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [263]
In the citing paper
“GLP-1 receptor agonists have a positive effect on weight loss in T2DM and do not show a negative effect on muscle mass.”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
General methods for monitoring convergence of iterative simulations
Brooks, S. P., & Gelman, A. (1998) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1998.10474787 · Cited by 6,045
Levesque, R. J. R. (2017) · Encyclopedia of Adolescence · doi:10.1007/978-3-319-32132-5_447-2 · Cited by 4,021
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053 · cited 1×
“Publication bias was assessed visually using contour enhanced funnel plots [12] for all comparisons that contained five or more studies.”
MethodDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“4 Pharmaceutical Buse (2009) [43] Exenatide 20μg Austria, Denmark, Finland, France, Germany, Ireland, Macedonia, Norway, Poland, Puerto Rico, Romania, Slovenia, Spain, Sweden, Switzerland, USA 231 6 32.”
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 1×
“1 59 36 Pharmaceutical Buse (2004) [9] Exenatide 20μg USA 125 6.”
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“A random effects mixed treatment comparison meta-analysis was conducted using a linear regression model adjusting for the fact that some trials had more than two treatment arms [13].”
MethodNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Cited by
Items 101–163 of 163
Albèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 15
“37 kg).(27) Also, the LEAD-6 study, a head-to-head trial including liraglutide 1.”
BackgroundJones, S., LUO, S. H., Dorton, H. M., Yunker, A. G., ANGELO, B. C., DEFENDIS, A. W., Monterosso, J. R., & Page, K. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.638504 · Cited by 16
“GLP-1 analogues have been found to be associated with weight loss in clinical populations with obesity and overweight with or without diabetes (34, 35, 37), but individual effectiveness of these weight loss therapies is highly variable.”
BackgroundAhmadi, S. S., Filipsson, K., Dimenäs, H., Isaksson, S. S., Imberg, H., Sjöberg, S., Åhrén, B., Dahlqvist, S., Gustafsson, T. P., Tuomilehto, J., et al. (2018) · Obesity Science & Practice · doi:10.1002/osp4.324 · Cited by 14
Kalirai, S., Stephenson, J. J., Perez‐Nieves, M., Grabner, M., Hadjiyianni, I., Geremakis, C. M., Pollom, R. D., Reed, B. L., & Fisher, L. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.10.001 · Cited by 15
Surgery for Diabetes: Clinical and Mechanistic Aspects
Kapeluto, J., Tchernof, A., & Biertho, L. D. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.008 · Cited by 18
“DJB is associated with increased GLP-1 secretion, but the outcomes in terms of weight loss and glycemic control with DJB more closely resemble those achieved with exogenous GLP-1 agonist therapy, further suggesting that caloric restriction resulting from a reduced stomach reservoir plays a significant role in improved…”
ResultFranch-Nadal, J., Granado-Casas, M., Mata-Cases, M., Ortega, E., Vlacho, B., & Mauricio, D. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.10.005 · Cited by 12
Wong, S., Le, G. H., Dri, C. E., Teopiz, K. M., & McIntyre, R. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16660 · Cited by 17
Meece, J. D. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0491-1 · Cited by 16
Guo, Z., Wu, Y., Zhu, L., Wang, Y., Wang, D., & Sun, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00908-1 · Cited by 9
Kataoka, H., Nomura, T., Oka, H., & Ikeda, Y. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70047 · Cited by 10
α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo
Shi, Y., Lee, C., Sang, P., Amso, Z., Huang, D., Zhong, W., Gu, M., Wei, L., Nguyen-Tran, V. T. B., Zhang, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.014 · Cited by 9
Gant, C. M., Mensink, I., Binnenmars, S. H., van der Palen, J. A. M., Bakker, S. J. L., Navis, G. J., & Laverman, G. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218400 · Cited by 9
Weight effects of antidiabetic agents
Higbea, A. M., Duval, C., Chastain, L. M., & Chae, J. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1395694 · Cited by 11
“glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have been touted to assist with weight loss in the diabetic patient [47].”
BackgroundWang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“The highlight of the meta-analysis is that the evaluation of the effects of GLP-1 receptor agonists on body composition in T2DM, particularly on indicators related to sarcopenia, revealed no significant differences [58, 71].”
Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes
Xing, Y., Chen, J., Zhao, L., & Ma, H. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0530 · Cited by 8
Bondarenko, V., Løkke, C. R., Dobrowolski, P., Mentzel, C. M. J., Castro-Mejía, J. L., Hansen, C. H. F., Sørensen, D. B., Nielsen, D. S., Krych, Ł., & Hansen, A. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-17242-8 · Cited by 10
Risović, I., Dumanovic, M. S., Bojić, M., & Djekic, D. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01282-w · Cited by 10
Rahman, E., Webb, W. R., Esfahlani, S. S., Rao, P., Garcia, P. E., Sayed, K., Ioannidis, S., Yu, N., Nassif, A. D., Goodman, G. J., et al. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012307 · Cited by 9
Bensignor, M. O., & Kelly, A. S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00738 · Cited by 7
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Ehrhardt, N. M., Aroda, V. R., Galindo, R. J., Peters, A. L., & Shubrook, J. H. (2023) · Clinical Diabetes · doi:10.2337/cd23-0047 · Cited by 6
Goron, A. R., Connolly, C. T., Valdez‐Sinon, A. N., Hesson, A., Helou, C. M., & Kirschen, G. W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206259 · Cited by 11
“Of particular note, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have revolutionized type 2 diabetes mellitus care and medical weight loss treatment, though their effects on physiology in patients undergoing surgery remain incompletely understood [52,53].”
BackgroundBusch, R. S., Ruggles, J., Han, J., & Hardy, E. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.13029 · Cited by 6
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Self-citationMorgan, C. L., Qiao, Q., Grandy, S., Johnsson, K. M., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0359-z · Cited by 5
“A potentially key contributing factor could be that exenatide is associated with weight loss [10, 11].”
BackgroundBlonde, L., Fainberg, U., Kaltoft, M. S., Mosenzon, O., Ramesh, C. K., & Rea, R. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14464 · Cited by 5
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Murphy, C. F., & le Roux, C. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.06 · Cited by 4
Weight loss mediates improvement in proinsulin processing during GLP-1 receptor agonist treatment
Liu, R., Hou, D., Leng, M., Li, Z., Zhang, Y., Liu, L., Wang, X., & Li, C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01765-x · Cited by 4
“While the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide, on glycemic control, improvement of IR, and reduction of obesity are well characterized [11–13].”
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
Rajagopalan, S., Zhong, J., & Goud, A. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s69354 · Cited by 4
“However, no significant difference in weight loss was seen between the different types of GLP-1 agonists.(23) Thus, a small but significant reduction in body weight is seen with all GLP-1 therapy.”
BackgroundNew antihyperglycaemic agents and cardiovascular disease: let's be optimistic
Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000524 · Cited by 6
Lingvay, I., Catarig, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Evans, L. M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01344-7 · Cited by 3
“GLP-1 RAs are an established treatment option for T2D, offering improved glycaemic control alongside weight management and cardiovascular benefits [14, 15].”
BackgroundAl‐Samiry, A. H., Mohammed, S. I., & Mubder, N. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v6i1.413 · Cited by 3
“These drugs, frequently categorized as incretin mimetics, are gaining popularity as a type 2 diabetes mellitus (T2DM) treatment option since they cause a moderate hemoglobin A1c decrease along with weight loss [3].”
BackgroundInfluentialEffectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients
Ghuman, N. K., Saadah, L. M., AlNajjar, M., Shaheen, D. Y., Shady, I. B., & Ali, M. M. A. (2015) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s31756 · Cited by 3
Xu, L., Yu, S. Q., Gao, L., Huang, Y., Wu, S., Yang, J., Sun, Y. X., Yang, Z., Chai, S. B., Zhang, Y., et al. (2020) · PubMed · doi:10.3967/bes2020.005 · Cited by 3
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2023) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
Glucagon-like peptide-1 agonists for weight loss in people with obesity
Kirk, S., Shamliyan, T., & Middleton, M. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.01.003 · Cited by 2
Current options for the treatment of obesity
Haluzík, M., Jakubíková, I., Kudláčková, M., & Horváth, L. (2023) · Medicína pro praxi · doi:10.36290/med.2023.036 · Cited by 2
Liraglutide: another reason to target prediabetes?
Murphy, C. F., Docherty, N. G., & le Roux, C. W. (2017) · Oncotarget · doi:10.18632/oncotarget.22256 · Cited by 3
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
“Many AHAs lead to weight gain, including insulin, SU, and glitazones [156,157].”
BackgroundSashi, Rani, K., Rani, K., Ankita, A., Mittal, V., Kaushik, D. K., Dhall, M., Bamrah, P. K., Kumar, T., Pandey, M., et al. (2024) · Current Drug Therapy · doi:10.2174/0115748855276929231218053337 · Cited by 1
Falkenberg, C., Sørensen, D. B., Hansen, C. H., Toft, M., & Hansen, A. K. (2024) · Laboratory Animals · doi:10.1177/00236772241279058 · Cited by 1
“23 Systemic immune activation may affect mouse behaviour.”
Gewichtsänderung als unerwünschte Arzneimittelwirkung
Engeli, S., & May, M. (2020) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1207-8003 · Cited by 2
“[10] Potts JE, Gray LJ, Brady EM et al.”
BackgroundTerapi Diabetes Melitus Tipe 2 Berbasis Hormon Inkretin
Antoni, M. (2023) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v29i2.2664 · Cited by 8
Emergence of GLP-1 Receptor Agonists as a Therapy for Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., & Tuttle, K. R. (2019) · Cited by 1
Inflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Reimão, S. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-14032018-122506
Mott, T. F., & Wilder, A. (2020) · Evidence-Based Practice · doi:10.1097/ebp.0000000000000527
“sitagliptin, or pioglitazone) or placebo for sixmonths.(3)Mean BMI of study participants ranged from 26 to 35, and mean agewas51 to60years.”
BackgroundVally, M. (2020) · South African General Practitioner · doi:10.36303/sagp.2020.1.1.0006
Guo, Z., Yuting, W., & Sun, X. (2021) · Research Square · doi:10.21203/rs.3.rs-520283/v1
Efeito do sistema incretínico sobre o recrutamento de adipócitos bege
Oliveira, F. C. B. (2018) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2018.02.t.32242
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Hypothalamic-pituitary dysfunction in children with suprasellar tumors: improving the outcome
van Schaïk, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1959
Risović, I., Djekic, D., Bojić, M., Markovic, A., Dojčinović, T., Vlatković, V., & Dobrovoljski, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3340824/v1
Wang, Z., Lavikainen, P., Wikström, K., & Laatikainen, T. K. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01763-2 · Cited by 3
“Despite being observed in trials [24, 25], the weight reduction associated with the new antidiabetic medications might not be easily seen at the patient population level.”
Yugar, L. B. T., Sedenho‐Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C., & Cercato, C. (2024) · Figshare · doi:10.6084/m9.figshare.25687387
Li, H., Jiang, C., Hu, X., Gao, X., Wan, J., Huang, L., Long, Y., Xu, X., & Xie, Q. (2026) · BMC Ophthalmology · doi:10.1186/s12886-026-04891-w
“In addition, insulin resistance and sympathetic nervous system activation have been proposed to increase aqueous humor production or raise outflow resistance, thereby contributing to higher IOP [25, 26].”
Lipska, K. J., Zawack, K., Yan, L., Mutalik, P., Li, J., Gulanski, B., Ioannou, G. N., & Aslan, M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05216
Glucagon-like peptide-1 improves mesangial proliferative glomerulonephritis in rats
Wang, X. Z., Wu, T., Tang, H. M., Deng, Y., & Li, C. H. (2018) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2018_042
Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
Ali, M. A., Das, S., Kumar, R. R., & Rabindra, K. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26oct881
“51,65,66,69 Recently, subcutaneous semaglutide has been shown to reduce body weight more effectively than placebo and more effectively than both dulaglutide and exenatide ER.49 Studies have shown that some once-weekly GLP-1 receptor agonists may reduce cardiovascular events and improve other…”
BindingDB (2020) · UC San Diego · doi:10.7270/q2fn18tn
Metadata
- Authors
- Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H.
- Affiliations
- University of Leicester (GB)
- University Hospitals of Leicester NHS Trust (GB)
- Corresponding author
- Bodicoat, Danielle H.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-29
- Volume
- 10
- Issue
- 6
- Pages
- e0126769
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4487255
- OpenAlex
- W1643809894
- Cited by
- 163
- References
- 44
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 12 · 2021: 17 · 2020: 19 · 2019: 17 · 2018: 29 · 2017: 20 · 2016: 11 · 2015: 4
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
- Funders
- University Hospitals of Leicester NHS Trust
- National Institute for Health and Care Research
- University of Leicester
- Loughborough University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, weight loss, type 2 diabetes, obesity, exenatide, liraglutide, antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Peptides, Venoms, Weight Loss, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.